FDA appears increasingly interested in decoupling the biosimilar user fee program from its older sibling for prescription drugs, in part to ensure its revenue stream is more predictable.
Biosimilar application fees now follow those for the Prescription Drug User Fee Act (PDUFA). A 351(k)'s application fee is the same as for an NDA, but BsUFA does already have...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?